CSF3 and non-Hodgkin lymphoma: Plerixafor in combination with granulocyte-colony stimulating factor (G-CSF) has been approved as mobiliser of haematopoietic CD34+ cells from the bone marrow to the circulation for patients with non-Hodgkin's lymphoma and multiple myeloma [2].